738 / 1241
Management of Prostate Cancer
Localised Disease:
Low risk
Intermediate risk
High risk
cStage
T1-2a
& PSA ng/mL <10
& Gleason ≤6
cStage
T2b-c
or PSA ng/mL 10-20
or Gleason 7
cStage
≥T3a
or PSA ng/mL >20
or Gleason 8-10
Active surveillance
Offer radical treatment
if progression
Radical prostatectomy
Radical radiotherapy
Active surveillance
if patient does not
wish to proceed to
radical treatment
immediately
Radical prostatectomy
Radical radiotherapy
± androgen deprivation
therapy
± brachytherapy
Source: NICE UK
Updated Jan 2014